COPD study seeks to personalize steroid treatment using blood markers
NCT ID NCT06334575
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This study aims to understand why some COPD patients benefit from inhaled corticosteroids (ICS) while others do not, by looking at molecular changes in the body. Researchers will enroll 135 former smokers with stable COPD who are already on dual bronchodilators. Participants will be grouped by their blood eosinophil levels and randomly assigned to receive ICS or continue usual care, with samples taken to identify molecular signatures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Academisch Ziekenhuis Groningen
RECRUITINGGroningen, Netherlands
-
Clínic Barcelona
RECRUITINGBarcelona, 08036, Spain
-
Imperial College London
NOT_YET_RECRUITINGLondon, United Kingdom
-
Philips University of Marburg
RECRUITINGMarburg, Germany
-
Son Espases
RECRUITINGPalma de Mallorca, 07120, Spain
-
University of Leicester
NOT_YET_RECRUITINGLeicester, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD